electroCore, Inc. ECOR
5.19 USD -0.06 (-1.14%)
As ofNov 16, 2026, 2:11 PM EST
4.99 Day range 5.75
4.37 52-week range 12.70
- YTD
- +15.59%
- 1 year
- -7.32%
Benzinga news
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…benzinga.com CORRECTION: electroCore Widens FY2026 Sales Guidance from $41.600M to $39.000M-$42.000M vs $41.915M Est electroCore (NASDAQ:ECOR) widens FY2026 sales outlook from $41.600 million to $39.000 million-$42.000 million vs $41.915 million estimate.
benzinga.com electroCore Q3 2026 Earnings Call Transcript electroCore (NASDAQ:ECOR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com electroCore Raises FY2026 Sales Guidance from $41.600M to $41.642M vs $41.915M Est electroCore (NASDAQ:ECOR) raises FY2026 sales outlook from $41.600 million to $41.642 million vs $41.915 million estimate.
benzinga.com electroCore Q3 EPS $(0.13) Beats $(0.27) Estimate, Sales $9.690M Miss $10.928M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 67.5 percent increase over losses of $(0.40)…
benzinga.com electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug
